270 related articles for article (PubMed ID: 21775207)
1. mTOR signaling in polycystic kidney disease.
Ibraghimov-Beskrovnaya O; Natoli TA
Trends Mol Med; 2011 Nov; 17(11):625-33. PubMed ID: 21775207
[TBL] [Abstract][Full Text] [Related]
2. [Recent advances in molecular pathogenesis and treatment of polycystic kidney disease].
Covic M; Covic M
Rev Med Chir Soc Med Nat Iasi; 2008; 112(1):11-20. PubMed ID: 18677899
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic advances in the treatment of polycystic kidney disease.
Riella C; Czarnecki PG; Steinman TI
Nephron Clin Pract; 2014; 128(3-4):297-302. PubMed ID: 25573484
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.
Renken C; Fischer DC; Kundt G; Gretz N; Haffner D
Nephrol Dial Transplant; 2011 Jan; 26(1):92-100. PubMed ID: 20615907
[TBL] [Abstract][Full Text] [Related]
5. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model.
Leonhard WN; van der Wal A; Novalic Z; Kunnen SJ; Gansevoort RT; Breuning MH; de Heer E; Peters DJ
Am J Physiol Renal Physiol; 2011 May; 300(5):F1193-202. PubMed ID: 21345977
[TBL] [Abstract][Full Text] [Related]
6. Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment.
Ponticelli C; Locatelli F
Nephrol Dial Transplant; 2010 Dec; 25(12):3809-12. PubMed ID: 20798121
[No Abstract] [Full Text] [Related]
7. Regulation of ciliary trafficking of polycystin-2 and the pathogenesis of autosomal dominant polycystic kidney disease.
Cai Y; Tang Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Feb; 35(2):93-9. PubMed ID: 20197605
[TBL] [Abstract][Full Text] [Related]
8. Pkd1 and Nek8 mutations affect cell-cell adhesion and cilia in cysts formed in kidney organ cultures.
Natoli TA; Gareski TC; Dackowski WR; Smith L; Bukanov NO; Russo RJ; Husson H; Matthews D; Piepenhagen P; Ibraghimov-Beskrovnaya O
Am J Physiol Renal Physiol; 2008 Jan; 294(1):F73-83. PubMed ID: 17928412
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.
Gattone VH; Wang X; Harris PC; Torres VE
Nat Med; 2003 Oct; 9(10):1323-6. PubMed ID: 14502283
[TBL] [Abstract][Full Text] [Related]
10. A genetic screen in zebrafish identifies cilia genes as a principal cause of cystic kidney.
Sun Z; Amsterdam A; Pazour GJ; Cole DG; Miller MS; Hopkins N
Development; 2004 Aug; 131(16):4085-93. PubMed ID: 15269167
[TBL] [Abstract][Full Text] [Related]
11. Elevated TGFbeta-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease.
Hassane S; Leonhard WN; van der Wal A; Hawinkels LJ; Lantinga-van Leeuwen IS; ten Dijke P; Breuning MH; de Heer E; Peters DJ
J Pathol; 2010 Sep; 222(1):21-31. PubMed ID: 20549648
[TBL] [Abstract][Full Text] [Related]
12. Polycystic kidney diseases: from molecular discoveries to targeted therapeutic strategies.
Ibraghimov-Beskrovnaya O; Bukanov N
Cell Mol Life Sci; 2008 Feb; 65(4):605-19. PubMed ID: 17975706
[TBL] [Abstract][Full Text] [Related]
13. Polycystic kidney disease: new knowledge and future promises.
Foo JN; Xia Y
Curr Opin Genet Dev; 2019 Jun; 56():69-75. PubMed ID: 31476629
[TBL] [Abstract][Full Text] [Related]
14. Polycystic kidney disease, cilia, and planar polarity.
Menezes LF; Germino GG
Methods Cell Biol; 2009; 94():273-97. PubMed ID: 20362096
[TBL] [Abstract][Full Text] [Related]
15. The PI3K/Akt/mTOR pathway in polycystic kidney disease: A complex interaction with polycystins and primary cilium.
Margaria JP; Campa CC; De Santis MC; Hirsch E; Franco I
Cell Signal; 2020 Feb; 66():109468. PubMed ID: 31715259
[TBL] [Abstract][Full Text] [Related]
16. Calcium signaling and polycystin-2.
Anyatonwu GI; Ehrlich BE
Biochem Biophys Res Commun; 2004 Oct; 322(4):1364-73. PubMed ID: 15336985
[TBL] [Abstract][Full Text] [Related]
17. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease.
Smith LA; Bukanov NO; Husson H; Russo RJ; Barry TC; Taylor AL; Beier DR; Ibraghimov-Beskrovnaya O
J Am Soc Nephrol; 2006 Oct; 17(10):2821-31. PubMed ID: 16928806
[TBL] [Abstract][Full Text] [Related]
18. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression.
Huber TB; Walz G; Kuehn EW
Kidney Int; 2011 Mar; 79(5):502-11. PubMed ID: 21085109
[TBL] [Abstract][Full Text] [Related]
19. A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease.
Kipp KR; Rezaei M; Lin L; Dewey EC; Weimbs T
Am J Physiol Renal Physiol; 2016 Apr; 310(8):F726-F731. PubMed ID: 26764208
[TBL] [Abstract][Full Text] [Related]
20. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Wüthrich RP; Kistler AD; Serra AL
Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
